Forest Laboratories, Inc. today announced that the U.S. FDA has approved the Company's supplemental New Drug Application for Lexapro (escitalopram oxalate) for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, 12 - 17 years of age. Lexapro is only the second antidepressant to be approved for the treatment of MDD in adolescents, a medical condition that affects approximately 2 million adolescents in the U.S.
The details can be read here.
No comments:
Post a Comment